We are developing a new generation of biotechnology drugs that act precisely within a targeted diseased tissue

About Valitor

Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity.

Our technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development

Our lead product will be used to improve the treatment of diseases in ophthalmology. We also have development pipelines for products in the fields of oncology and orthopedics.

About Valitor

Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity.

Our technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development.

Our lead product will be used to improve the treatment of diseases in ophthalmology. We also have development pipelines for products in the fields of oncology and orthopedics.

 

Our Technology

Our Technology

We have developed methods to tether bioactive molecules (e.g., growth factors, antibodies, receptor ligands, etc.) to single-chain, soluble biopolymers such as hyaluronic acid.

+

=

Therapeutic proteins

Biopolymer

Protein conjugates

By coupling one or more bioactive molecules to the polymers at defined ratios, we can formulate drugs with the following advantages over unmodified drug products: 

1. Enhanced efficacy after local administration

2. Less frequent administration (more convenient and improved safety)

3. Enable the use of best-in-class drugs for new clinical indications

Using this technology, we have initiated the development of three protein-based therapies that we expect will dramatically improve the current treatment strategies for a variety of diseases.

 

Team

Board of Directors

 

Wesley Jackson, PhD

Chief Executive Officer

David Schaffer, PhD

Executive Science Advisor

Paul Shields

Executive CMC/Operations Advisor

Drew Lanza, MBA

Director

Walter Moos, PhD

Director

lbrier-1_orig.jpg

Livia Brier, PhD

Director of Preclinical Studies

atwite2_orig.jpg

Amy A. Twite, PhD

Director of Chemistry

Jesse McFarland, PhD

Director of Process Development

Kevin Healy, PhD

Co-Founder and Director

Gail Maderis, MBA

Independent Director

Investors
Phaenomena West Logo.png
Government agencies
Awards, Accelerators, and Competitions

Semi finalist 2011

California JumpStart Award 2016

 
Contact Us

Valitor, Inc.
East Bay Innovation Center
820 Heinz Avenue
Berkeley, CA 94710

Phone: (510) 545-6062
Fax: (510) 647-8429
Email: info@valitorbio.com

For any general inquiries, please fill in the following contact form:

 

© Valitor, Inc 2020

  • LinkedIn - White Circle